Synapse - Genitourinary Oncology Service

Results (5696)

Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM

Meeting Abstract

Armstrong, A. J.; Saad, F.; Shore, N. D.; Fizazi, K.; Phung, D.; Dmuchowski, C.; Hirmand, M.; Forer, D.; Scher, H. I.; De Bono, J. S.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Cardiovascular disease (CVD) risk factors and health behaviors after cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS) in the Platinum study

Meeting Abstract

Abu Zaid, M. I.; Fung, C.; Williams, A.; Sesso, H. D.; Kerns, S. L.; Ardeshir-Rouhani-Fard, S.; Feldman, D. R.; Hamilton, R. J.; Vaughn, D. J.; Beard, C.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Immune activation by PEGylated human IL-10 (AM0010) and anti-tumor activity in renal cancer alone and in combination with anti-PD-1

Meeting Abstract

Naing, A.; Papadopoulos, K. P.; Autio, K. A.; Wong, D. J.; Patel, M.; Falchook, G.; Pant, S.; Ott, P. A.; Whiteside, M.; Patnaik, A.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

CX-839-004: A phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer

Meeting Abstract

Lam, E.; Tannir, N. M.; Meric-Bernstam, F.; Vaishampayan, U.; Orford, K. W.; Molineaux, C.; Gross, M.; MacKinnon, A.; Voss, M.
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

KEYNOTE-057: Phase II study of pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)

Meeting Abstract

Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R.; Siefker-Radtke, A.; Sonpavde, G.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: The phase III JAVELIN Renal 101 trial

Meeting Abstract

Rini, B. I.; Choueiri, T. K.; Mariani, M.; Albiges, L.; Haanen, J. B.; Atkins, M. B.; Larkin, J.; Schmidinger, M.; Magazzù, D.; di Pietro, A.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study

Meeting Abstract

Sharma, P.; Callahan, M. K.; Calvo, E.; Kim, J. W.; de Braud, F.; Ott, P. A.; Bono, P.; Pillai, R. N.; Morse, M.; Le, D. T.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Keynote-045: Open-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer

Meeting Abstract

Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Phase I study of everolimus in combination with gemcitabine and split-dose cisplatin in advanced urothelial carcinoma

Journal Article

Abida, W.; Milowsky, M. I.; Ostrovnaya, I.; Gerst, S. R.; Rosenberg, J. E.; Voss, M. H.; Apolo, A. B.; Regazzi, A. M.; McCoy, A. S.; Boyd, M. E.; more...
Bladder Cancer (2016)

Fulltext@MSK | Save

Mutational analysis of clonal hematopoiesis in solid tumor patients illustrates the critical role of systemic anti-cancer therapies in the evolution of somatic leukemia disease alleles

Meeting Abstract

Coombs, C. C.; Zehir, A.; Devlin, S.; Kishtagari, A.; Hyman, D. M.; Solit, D.; Robson, M.; Baselga, J.; Arcila, M.; Tallman, M. S.; more...
Blood (2016)

Fulltext@MSK | Save